These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

883 related items for PubMed ID: 18465450

  • 1. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC, Chung SJ, Park YB, Lee SK.
    Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
    [Abstract] [Full Text] [Related]

  • 2. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM, Pejnovic NN, Sefik-Bukilica MN, Kovacevic LV, Soldatovic II, Damjanov NS.
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [Abstract] [Full Text] [Related]

  • 3. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC.
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [Abstract] [Full Text] [Related]

  • 4. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 19; 86(35):2451-4. PubMed ID: 17156669
    [Abstract] [Full Text] [Related]

  • 5. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.
    Tokayer A, Carsons SE, Chokshi B, Santiago-Schwarz F.
    J Rheumatol; 2002 Mar 19; 29(3):454-61. PubMed ID: 11908556
    [Abstract] [Full Text] [Related]

  • 6. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis.
    Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J.
    Scand J Rheumatol; 2009 Mar 19; 38(6):439-44. PubMed ID: 19922018
    [Abstract] [Full Text] [Related]

  • 7. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC.
    Arthritis Rheum; 2008 Aug 19; 58(8):2257-67. PubMed ID: 18668547
    [Abstract] [Full Text] [Related]

  • 8. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.
    Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP.
    Arthritis Rheum; 2010 Jan 19; 62(1):150-8. PubMed ID: 20039407
    [Abstract] [Full Text] [Related]

  • 9. Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis.
    Schotte H, Schlüter B, Willeke P, Mickholz E, Schorat MA, Domschke W, Gaubitz M.
    Rheumatology (Oxford); 2004 Aug 19; 43(8):960-4. PubMed ID: 15026584
    [Abstract] [Full Text] [Related]

  • 10. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease.
    Chen DY, Hsieh TY, Chen YM, Hsieh CW, Lan JL, Lin FJ.
    Gerontology; 2009 Aug 19; 55(3):250-8. PubMed ID: 18849599
    [Abstract] [Full Text] [Related]

  • 11. Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis.
    Yazdani-Biuki B, Stadlmaier E, Mulabecirovic A, Brezinschek R, Tilz G, Demel U, Mueller T, Brickmann K, Graninger WB, Brezinschek HP.
    Ann Rheum Dis; 2005 Aug 19; 64(8):1224-6. PubMed ID: 16014683
    [Abstract] [Full Text] [Related]

  • 12. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug 19; 28(8):1349-51. PubMed ID: 18753057
    [Abstract] [Full Text] [Related]

  • 13. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M, Zwicker M, Villiger PM.
    J Rheumatol; 2003 Jan 19; 30(1):28-35. PubMed ID: 12508386
    [Abstract] [Full Text] [Related]

  • 14. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
    Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D, Mattei JP, Nogueira L, Mugnier B, Legeron P, Landt O, Serre G, Roudier J, Roudier C.
    Arthritis Rheum; 2007 Dec 15; 57(8):1426-30. PubMed ID: 18050183
    [Abstract] [Full Text] [Related]

  • 15. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul 15; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

  • 16. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M, Wirthmüller U, Möller B, Villiger PM.
    Rheumatology (Oxford); 2007 Jan 15; 46(1):93-6. PubMed ID: 16720636
    [Abstract] [Full Text] [Related]

  • 17. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study.
    Jamnitski A, Visman IM, Peters MJ, Dijkmans BA, Voskuyl AE, Nurmohamed MT.
    Ann Rheum Dis; 2010 Nov 15; 69(11):1929-33. PubMed ID: 20498216
    [Abstract] [Full Text] [Related]

  • 18. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis.
    Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK.
    Rheumatology (Oxford); 2008 Dec 15; 47(12):1775-9. PubMed ID: 18854347
    [Abstract] [Full Text] [Related]

  • 19. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A.
    J Rheumatol; 2006 Mar 15; 33(3):497-500. PubMed ID: 16511906
    [Abstract] [Full Text] [Related]

  • 20. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
    Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer T, Yazici H, Guerne PA.
    J Rheumatol; 1997 Feb 15; 24(2):303-8. PubMed ID: 9034987
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.